Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 5Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Melanoma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Sarcoma, Ewing 1SCLC 1Retinoblastoma 1Osteosarcoma 1Oligometastatic Disease 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Carcinoma 1NSCLC 1Mouth Neoplasms 1Lymphoma, Follicular 1Lymphoma 1Locally Advanced Resectable Rectal Cancer 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1

Interventions

pegfilgrastim 1balugrastim 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Chemotherapy-induced Neutropenia × Drug Therapy × Clear all
NCT00837265 2024-04-03

NEUGR-002

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2/3 Completed
334 enrolled 16 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡